Atest specimen in a tensile test has a gage length of 2.0 in and an area = 0.5in^2. during the test the specimen yields under a load of 32,000 lb. the corresponding gage length = 2.0083 in. this is the 0.2% yield point. the maximum load of 60,000 lb is reached at a gage length = 2.6 in. determine a) yield strength, b) madulus of elasticity, and c) ten

Amodel rocket with a mass of 0.212 kg is launched into the air with an initial speed of 84 m/s. how much kinetic energy will the rocket have at a height of 214 m? assume there is no wind resistance. 634 j 303 j

The bubba chump shrimp company processes and packages shrimp for sale to wholesale seafood distributors. the shrimp are transported to the main plant by trucks that carry 1,000 pounds (lb) of shrimp. once the continuous flow processing of the shrimp begins, no inventory is allowed in buffers due to spoilage and all of the shrimp must be processed within 12 hours to prevent spoilage. the processing begins at the sorter, where the trucks dump the shrimp onto a conveyor belt that feeds into the sorter, which can sort up to 500 lb per hour. the shrimp then proceed to the desheller, which can process shrimp at the rate of 400 lb per hour. however, after 3 hours and 45 minutes of processing, the desheller must be stopped for 15 minutes to clean out empty shrimp shells that have accumulated. the veins of the shrimp are then removed in the deveining area at a maximum rate of 360 lb per hour. the shrimp proceed to the washing area, where they are processed at 750 lb per hour. finally, the shrimp are packaged and frozen. what is the daily process capacity of the processing plant (excluding the packaging and freezing)?

Asubject in a clinical research trial experiences a serious, unanticipated adverse drug experience. how should the investigator proceed, with respect to the irb, after the discovery of the adverse event occurrence? a. do not report the adverse drug experience to the irb since it is a common adverse experience. b. report the adverse drug experience to the irb only if there are several other occurrences. c. report the adverse drug experience as part of the continuing review report. d. report the adverse drug experience in a timely manner, in keeping with the irb's policies and procedures, using the forms or the mechanism provided by the irb.